NUFORMIX PLC

Board/Management Information • Oct 10, 2025

National Storage Mechanism | Additional information

RNS Number : 8140C

Nuformix PLC

10 October 2025

10 October 2025

Nuformix plc

("Nuformix" or the "Company")

Change of Auditor

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the appointment of Kreston Reeves Audit LLP ("Kreston Reeves Audit") as auditor to the Company.  The appointment of Kreston Reeves Audit follows a restructuring of the audit practice of Kreston Reeves LLP, the Company's former auditor, and will be subject to approval by shareholders at the next Annual General Meeting of the Company.

Enquiries:

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
CMC Markets
Douglas Crippen	+44 (0) 20 3003 8632
IFC Advisory Limited
Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6630 [email protected]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.  Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPEAKENEDESFFA